Follow us on Twitter
twitter icon@FreshPatents


G Protein patents

      

This page is updated frequently with new G Protein-related patent applications.




 Protein functional and sub-cellular annotation in a proteome patent thumbnailnew patent Protein functional and sub-cellular annotation in a proteome
Techniques are disclosed for identifying the likely functionality and sub-cellular localization of individual proteins by first creating a protein-protein interaction network where protein pairs are created from data available from databases and experimental results, and by guessing potential interacting protein pairs where no data exists. Inside each protein pair, mutual likely functionality and localization annotations are made using the known functionalities and localization of the two proteins.
Insybio Ltd


 Tnt based diagnosis of paroxysmal atrial fibrillation patent thumbnailnew patent Tnt based diagnosis of paroxysmal atrial fibrillation
The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac troponin, nt-probnp (n-terminal prohormone of brain natriuretic peptide), hscrp, il-6 (interleukin-6) and igfbp7 (insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts).
Roche Diagnostics Operations, Inc.


 Stabilizied bioactive peptides and methods of identification, synthesis and use patent thumbnailnew patent Stabilizied bioactive peptides and methods of identification, synthesis and use
An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon.
Peptide Biosciences, Inc.


 Individualized cancer therapy patent thumbnailnew patent Individualized cancer therapy
In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and rna from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2d dige and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate rna interference expression cassette to, directly or indirectly, modulate the expression of genes encoding such prioritized proteins; (i) incorporating said cassette into an appropriate delivery vehicle; and (j) providing the patient with an effective amount of the delivery vehicle to directly or indirectly, modify the expression (i.e., production) of such proteins.. .
Gradalis, Inc.


 Methods and compositions for genomic target enrichment and selective dna sequencing patent thumbnailnew patent Methods and compositions for genomic target enrichment and selective dna sequencing
It has been established that one or more large double stranded dna fragments (each 2,000 to 40,000 base pairs in size) can be captured and isolated from genomic dna fragments using sequence specific pna hybridization probes. Compositions and methods for enrichment of a multiplicity of long dna sequences selected from the genome of any eukaryote are provided.
Petaomics, Inc.


 Fluorescent two-hybrid (f2h) assay for direct visualization of protein interactions in living cells patent thumbnailnew patent Fluorescent two-hybrid (f2h) assay for direct visualization of protein interactions in living cells
The present invention relates to a method for detecting protein-protein interactions by assessing interaction in a eukaryotic cell of a first fusion protein that specifically binds to gfp and accumulates at distinct sites in the nucleus of the cell or interacts with structures accumulated at distinct sites in the nucleus of the cell; a second fusion protein comprising gfp and a bait (poly)peptide; and a third fusion protein comprising a fluorescent (poly)peptide having an excitation and/or emission wavelength that differs from that of gfp and a prey (poly)peptide. The emissions from the fluorescent parts of the fusion proteins are observed.
Ludwig-maximilians-universitat Munchen


 Bacteria and enzymes produced therefrom and methods of using same patent thumbnailnew patent Bacteria and enzymes produced therefrom and methods of using same
A bacteria referred to here as bacillus subtilis 6a-1 is provided, compositions thereof and processes for use of the bacteria, spores, cells, extracts and enzymes. The compositions which comprise the bacteria, spores, cells, extracts and/or enzymes are capable of degrading polysaccharides.
Agri-king, Inc.


 Anti-activin a antibodies and uses thereof patent thumbnailnew patent Anti-activin a antibodies and uses thereof
The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.


 Mrka polypeptides, antibodies, and uses thereof patent thumbnailnew patent Mrka polypeptides, antibodies, and uses thereof
The present disclosure provides mrka binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to mrka and induce opsonophagocytic killing of klebsiella (e.g., klebsiella pneumoniae). The present disclosure also provides methods of reducing klebsiella (e.g., klebsiella pneumoniae) or treating or preventing klebsiella (e.g., klebsiella pneumoniae) infection in a subject comprising administering mrka binding proteins, e.g., antibodies or antigen-binding fragments thereof, mrka polypeptides, immunogenic fragments thereof, or polynucleotides encoding mrka or immunogenic fragments thereof to the subject..
Medimmune, Llc


 Fused heterocyclic compounds as protein kinase inhibitors patent thumbnailnew patent Fused heterocyclic compounds as protein kinase inhibitors
The invention is fused heterocyclic compounds of formula (i), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including bruton's tyrosine kinase (btk), and for treating disorders mediated thereby..
Beigene, Ltd.


new patent

Methods of treatment using hemopexin compositions

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof..
Csl Behring Ag

new patent

Mutant ros expression in human cancer

The invention provides the identification of the presence of mutant ros protein in human cancer. In some embodiments, the mutant ros are fig-ros fusion proteins comprising part of the fig protein fused to the kinase domain of the ros kinase.
Cell Signaling Technology, Inc.

new patent

Novel inhibitors for erg oncogene positive cancers

Alterations to the erg gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type erg protein or an altered erg protein.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

Method for high-throughput protein detection with two antibody microarrays

The invention provides a method for detecting one or more biological ligands, where the method generally uses two arrays of biological reagents. The two arrays have two different functionalities: the first array captures the ligands on the array; and the second array delivers detecting reagents to the captured ligands.

Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Embodiments of the invention provide swallowable devices, preparations and methods for delivering therapeutic agents within the gi tract such as neutralizing proteins (np) particularly antibodies which neutralize interleukins. Many embodiments provide a swallowable device e.g., a capsule for delivering various agents into the intestinal wall (iw).
Rani Therapeutics, Llc

Continuous process for separation of proteins

Disclosed is a continuous process for separating or extracting proteins from a low grade mixture of a protein of interest, other proteins, impurities, and salts in a continuous simulated moving bed separation process. The invention provides for direct extraction of heme protein and plant protein from a crude mixture of such proteins, other proteins, impurities and salts using the chromatographic technique of simulated moving bed (smb) continuous chromatography.
Orochem Technologies, Inc.

Compounds and methods for the targeted degradation of bromodomain-containing proteins

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a vhl ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein.
Yale University

Methods of modulating an immune response

The present invention relates to methods of modulating an immune response in a subject by using a binding protein (e.g., an antibody or an antigen-binding portion of an antibody) to mask or alter an epitope on an antigen that is administered to the subject. Such methods are useful for inducing an immune response (e.g., production of an antibody) in the subject to a non-immunodominant epitope on the antigen.
Cangene Corporation

Uses of starch binding protein (sbp)-tagged immunostimulatory protein

The present invention relates to a method for preventing or treating virus and protozoa infection in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (sbp)-tagged immunostimulatory protein and a sbp-binding matrix, wherein the immunostimulatory protein is from ganoderma species. The present invention also relates to a method for inducing interferon-gamma production in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (sbp)-tagged immunostimulatory protein and a sbp-binding matrix, wherein the immunostimulatory protein is from ganoderma species.
Simpson Biotech Co., Ltd

Par-1 activation by metalloproteinase-1 (mmp-1)

Matrix metalloproteases (mmps) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (par-1) by endogenous platelet mmp-1 collagenase on the surface of platelets.
Tufts Medical Center, Inc.

Green technology for crosslinking protein molecules for various uses

The present disclosure relates to, inter alia, a green technology for crosslinking protein molecules for various uses, where the protein molecules can be contained in protein fibers such as, but not limited to, human hair, animal fibers, and mixtures thereof. In one aspect, the present disclosure relates to a crosslinking agent comprising an oxidized sugar having at least two aldehyde groups.
Cornell University

In vitro diagnostic and prognosis of major adverse events in patients undergoing coronary angiography

Method of diagnosis and prognosis of contrast media induced nephropathy (cin) comprising the steps of i) taking a urine sample from a patient exposed to the application of contrast media, notably patients subjected to coronary angiography; ii) assessing the level of vitamin d binding protein (vdbp) in the urine sample obtained in step (i); iii) relating the urinary vitamin d binding protein level determined in step (ii) to a pre-selected threshold level, wherein a urinary vitamin d binding level higher than said pre-selected threshold level indicates that the patient is at risk of renal failure and in need of a dialysis treatment.. .
Immundiagnostik Ag

Protein detection method using mass spectrometry

The present invention provides: a method of pretreating a serum or plasma sample for detection of a protein or a plurality of proteins of interest in a serum or plasma sample via mass spectrometry and a method of detecting such a protein or proteins, wherein proteins such as albumin present in abundance in a sample are removed in a convenient manner, thereby making it possible to collect digested peptides from the protein of interest. Specifically, the present invention provides a method of pretreating a sample for detecting proteins in a serum or plasma sample via mass spectrometry, comprising a step of adding a protease to the sample under non-denaturing conditions to digest proteins and a step of separating the obtained peptides from undigested proteins, and a method of detecting proteins, comprising subjecting the obtained peptides to mass spectrometry..
Shimadzu Corporation

Therapies for cancer using rlip76

The present invention is a composition identified as a region of rala binding protein 1, wherein the region neighbors a membrane-associated portion of the rala binding protein 1, reduces transport activity and membrane association of the rala binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells.
Board Of Regents, The University Of Texas System

Mapping protein bound regions on dsdna by reaction of unblocked thymidines with osmium tetroxide 2,2'-bipyridine.

Materials, methods, and systems for determining the position, i.e. The sequence within a double stranded nucleic acid, where a protein is bound are disclosed and described.

Method of improving the movement of a target polynucleotide with respect to a transmembrane pore

The invention relates to improving the movement of a target polynucleotide with respect to a transmembrane pore when the movement is controlled by a polynucleotide binding protein. The invention also relates to improved transmembrane pores and polynucleotide binding proteins..
Oxford Nanopore Technologies Ltd.

Novel glycosyltransferase gene and use thereof

Provided is a polynucleotide for encoding a protein that exhibits activity for transferring a sugar to a hydroxyl group at position 7 of a flavone, particularly flavone 4′-glucoside. A polynucleotide selected from the group consisting of: (a) polynucleotides comprising a base sequence of seq id no.: 1 or seq id no.: 5; (b) polynucleotides that hybridize, under stringent conditions, with polynucleotides comprising a base sequence complementary to a base sequence of seq id no.: 1 or seq id no.: 5, wherein the polynucleotides encode a protein that exhibits activity for transferring a sugar to a hydroxyl group at position 7 of a flavone; (c) polynucleotides for encoding proteins comprising an amino acid sequence of seq id no.: 2 or seq id no.: 6; (d) polynucleotides for encoding proteins comprising an amino acid sequence in which one or more amino acids have been deleted, substituted, inserted, and/or added in an amino acid sequence of seq id no.: 2 or seq id no.: 6, the polynucleotides exhibiting activity for transferring a sugar to a hydroxyl group at position 7 of a flavone; and the like..
Suntory Holdings Limited

Il-1 binding proteins

Proteins that bind il-1α and il-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing il-1-related disorders and for detecting il-1α and il-1β in cells, tissues, samples, and compositions.. .
Abbvie Inc.

Novel glycosaminoglycan-antagonising fusion proteins and methods of using same

The present invention relates to novel monomeric fusion proteins derived from human gag binding proteins such as chemokines with increased glycosaminoglycan (gag) binding affinity and knocked-out or reduced gpcr activity compared to wild type gag binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.. .
Antagonis Biotherapeutics Gmbh

Peptides for treating cancer

The invention relates to novel peptides having an hdm-2 targeting sequence that target the human minute binding protein-2. The invention also relates to fusion proteins comprising a hdm-2 targeting sequence.

Mineral water composition containing bioavailable iron

A non-toxic artificial mineral water composition containing bioavailable iron consists of an aqueous solution having ph of from 1 to 5 containing ferrous ions at a concentration of from 100 to 300 mg/l and a non-toxic amount of at least one metal cation selected from ca2+, mg2+, zn2+ and k+, and wherein the composition, when diluted to an iron concentration of 20 μm, has an iron uptake, measured as intracellular ferritin, of greater than 120 ng/mg protein. The mineral water composition provides oral, bioavailable iron that has use as a supplement to dietary iron..
Snowdonia Research Sarl

Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase

The present invention relates to a method for the production of a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 as well as a method for selecting from a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide.. .
Eidgenoessische Technische Hochschule Zurich

Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides

This document relates to inhibitors of g protein coupled receptor 6 kinase (grk6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.. .
Mayo Foundation For Medical Education And Research

Small molecule inhibitors of g protein coupled receptor 6 kinase polypeptides

This document relates to inhibitors of g protein coupled receptor 6 kinase (grk6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.. .
Mayo Foundation For Medical Education And Research

Expression systems

The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a t cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic b cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture..
Glaxosmithkline Biologicals S.a.

Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease

The present invention relates to a pharmaceutical composition containing a g protein coupled receptor 119 (gpr119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the gpr119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the gpr119 ligand can be useful to treat non-alcoholic fatty liver..
Snu R&db Foundation

Production of protein-polysaccharide conjugates

The present invention provides novel compositions and methods for producing protein-polysaccharide conjugates in aqueous solutions. Also provided are methods for limiting the maillard reaction to the very initial stage, the formation of the schiff base.
Wisconsin Alumni Research Foundation

Nutritional compositions for bees

A high-protein nutritional composition for bees including protein derived from at least two sources including corn gluten, lipid derived from at least two sources including corn gluten, and carbohydrate.. .



G Protein topics:
  • Antibodies
  • Nucleic Acid
  • G Proteins
  • Nucleic Acids
  • Amino Acid
  • Polypeptide
  • Protein A Affinity Chromatography
  • Chromatography
  • Chromatograph
  • Liver Metastasis
  • Membrane Protein
  • Colorectal Carcinoma
  • Rectal Carcinoma
  • Prophylactic
  • Glycoprotein


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.


    2.128

    file didn't exist2499

    479091 - 0 - 55